Evergrande Group is China's second-largest property developer by sales.
In 2019, Evergrande Health's revenue reached CNY 5.64 billion, up 79.9% year on year. The net loss was CNY 4.95 billion, compared with a loss of CNY 1.43 billion in the same period last year, up 246.2% from the same period last year.It is mainly because the new energy vehicle business is still in the stage of investment expansion, the purchase of fixed assets and equipment, and the increase of research and development and other related expenses.
China's top4 real estate companies are Biguiyuan (HK: 02007) with CNY 732.95 billion, Vanke (SZ: 000002) with CNY 624.9 billion, Evergrande (HK: 03333) with CNY601.92 billion, Sunac China (HK: 01918) with CNY 527.85 billion.
Tri-party research organization led by Evergrande, representing the current leading forces in respiratory diseases, cancer and medical research. They have great hope to complete the mission of conquering novel coronavirus.
It is estimated that the company's EPS from 2019 to 2021 will be CNY 4.46, 6.01 and 7.29 respectively, and the dynamic P/E corresponding to the current share price will be 5.2, 3.8 and 3.2 times respectively. Considering the steady improvement of the company's profitability, the company will be valued at 7 times in 2019, corresponding to the target price of 36.55 Hong Kong dollars
The company is expected to enjoy a compound annual growth rate of 48.1% in net profit attributable to the parent from 2018 to 2020. Considering the company's abundant cargo value, fast performance and continuous improvement of safety, the company is valued at 8 times in 2018, corresponding to the target price of HK $33.42